{"id":3962,"date":"2026-10-28T09:00:00","date_gmt":"2026-10-28T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3962"},"modified":"2026-10-28T20:49:40","modified_gmt":"2026-10-29T00:49:40","slug":"china-accepts-sac-tmt-lung-cancer-filing","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3962","title":{"rendered":"China Accepts Sac TMT Lung Cancer Filing"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Kelun-Biotech<\/p>\n

Event Type<\/strong><\/p>\n

Regulatory filing acceptance (China-source update)<\/p>\n

Modality<\/strong><\/p>\n

TROP2-directed antibody-drug conjugate plus anti-PD-1<\/p>\n

Asset<\/strong><\/p>\n

Sacituzumab tirumotecan (SKB264\/MK-2870) plus pembrolizumab<\/p>\n

Target<\/strong><\/p>\n

TROP2; PD-1<\/p>\n

Disease Area<\/strong><\/p>\n

First-line PD-L1-negative, EGFR\/ALK-negative nonsquamous NSCLC<\/p>\n

Summary<\/h4>\n

China-source update: Kelun-Biotech\u2019s Chinese-language newsroom listed on 28 October that CDE accepted a seventh sac-TMT indication filing for first-line PD-L1-negative, EGFR\/ALK-negative nonsquamous NSCLC with pembrolizumab. The underlying Phase III OptiTROP-Lung06 data were reported earlier, so this is a regulatory filing update rather than a new readout.<\/p>\n

The company says the filing was accepted on 27 October. It cites centrally reviewed PFS 15.0 versus 5.7 months, HR 0.49, and response duration 13.6 versus 6.8 months from the earlier trial presentation. Acceptance is administrative review entry, not NMPA approval. An independently accessible CDE acceptance record was not recovered in this pass.<\/p>\n

Deep Analysis<\/h4>\n

The filing advances a China-local route for a TROP2 ADC plus PD-1 regimen in a biomarker-defined first-line group with no PD-L1 expression. The active chemoimmunotherapy comparator makes the PFS difference clinically relevant, but the prior data and safety profile must be assessed separately from the filing event. China trial enrollment and local treatment context do not guarantee global portability; overall survival, grade-specific toxicity and global replication remain decisive. Licensing rights for MK-2870 outside China further complicate cross-border timing.<\/p>\n

Company and Product Background<\/h4>\n

Sacituzumab tirumotecan (sac-TMT; SKB264\/MK-2870) is a TROP2-directed antibody-drug conjugate carrying a topoisomerase-I payload. Pembrolizumab blocks PD-1.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> CDE acceptance confirms the application package is sufficiently complete for review; company disclosure supports it.<\/li>\n
  • Interpretation B:<\/strong> acceptance has little bearing on approvability, especially without mature survival.<\/li>\n
  • Upgrade<\/strong> with a visible CDE record, review outcome and final OS. Downgrade<\/strong> with a major deficiency letter or adverse safety update. Refusal or withdrawal would falsify<\/strong> near-term China approval expectations.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: this is a material China regulatory step, with lower factual confidence than regulator-confirmed actions and no new efficacy inference.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: neutral regulatory progress. Confidence in Facts: moderate pending CDE record. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"

    China-source update: Kelun-Biotech\u2019s Chinese-language newsroom listed on 28 October that CDE accepted a seventh sac-TMT indication filing for first-line PD-L1-negative, EGFR\/ALK-negative nonsquamous NSCLC with pembrolizumab. The underlying Phase III OptiTROP-Lung06 data were reported earlier,…<\/p>\n","protected":false},"author":1,"featured_media":3971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1270,1216,1269,1271,1217],"class_list":["post-3962","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-china-nmpa","tag-kelun-biotech","tag-nsclc","tag-regulatory","tag-sacituzumab-tirumotecan"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3962"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3962\/revisions"}],"predecessor-version":[{"id":3978,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3962\/revisions\/3978"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3971"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}